We cultured the extraprostatic tissue devoid of normal prostate glands, and the organoids had squamous features and displayed positive pan-cytokeratin and very low AR staining. The established organoid line exhibits a double time of 5 days.
MSK-PCa6 is developed from a patient who underwent combined ADT and radiotherapy for Gleason 4+3 adenocarcinoma. Seven years after diagnosis, he developed symptomatic local recurrence with low PSA. Salvage prostatectomy showed residual adenocarcinoma with extensive squamous differentiation and invasion into the bladder and rectum.
- Yu Chen, MD, PhD, Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center
- Dong Gao, PhD, formerly at Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center
Gao D, et al. Organoid Cultures Derived from Patients with Advanced Prostate Cancer. Cell, 2014;159(1):176-87.
This organoid cell line may be licensed nonexclusively for research or commercial purposes.
For licensing requests: Alexandra Buga, MBA, Licensing Associate, Office of Technology Development, MSK, 646-888-1078, email@example.com.